Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen

Philip Lazarus, Andrea S. Blevins-Primeau, Yan Zheng, Dongxiao Sun

Research output: Chapter in Book/Report/Conference proceedingConference contribution

46 Scopus citations


Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor-positive (ER +) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30-50% reduction in both the rate of disease recurrence after 10 years of patient follow-up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM-induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.

Original languageEnglish (US)
Title of host publicationSteroid Enzymes and Cancer
PublisherBlackwell Publishing Inc.
Number of pages13
ISBN (Print)9781573317450
StatePublished - Feb 2009

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

All Science Journal Classification (ASJC) codes

  • General Neuroscience
  • General Biochemistry, Genetics and Molecular Biology
  • History and Philosophy of Science


Dive into the research topics of 'Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen'. Together they form a unique fingerprint.

Cite this